Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HOECHST-ROUSSEL's ENDOMETRIOSIS AGENT GESTRINONE

Executive Summary

HOECHST-ROUSSEL's ENDOMETRIOSIS AGENT GESTRINONE is in Phase II testing in the U.S. as an anti-estrogen, weak anti-progesterone and weak androgen-antagonist steroid. Roussel UCLAF currently markets the product, also known in research as R2323, in Brazil. The company hopes to market it in France in 1988 and in the near future in South Africa, Belgium and Holland. In France, the product is trademarked by Roussel UCLAF as Nemestran. A U.S. trademark filing for that name published for opposition under the international classification appeared in the April 14 "Official Gazette of the Patent and Trademark Office." A 35-patient study recently published in the "British Medical Journal," showed that there was no progression of the disease in the 18 patients receiving gestrinone, compared to a deterioration in eight of the 17 patients prescribed placebo. The study compared the gestrinone results to a deterioration rate of 23% in untreated patients. The study showed a difference in the elimination of the endometriosis favoring the gestrinone group, but the difference was not statistically significant. A significant difference in improvement of the disease with use of the drug was found, and the study concluded that gestrinone is an effective treatment of endometriosis. The British study (at Jessop Hospital for Women in Sheffield) is described as the first double blind, randomized placebo controlled trial of any treatment of endometriosis.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS011871

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel